The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Moderna coronavirus jab rolled out in England, adding to NHS "armoury"

Mon, 19th Apr 2021 14:42

(Alliance News) - NHS patients in England are to receive the Moderna Inc Covid-19 vaccine from Tuesday, officials have confirmed.

Stephen Powis, medical director for NHS England, said the move "marks another milestone" in the coronavirus vaccination programme.

And a member of the Joint Committee of Vaccination & Immunisation said the announcement paves the way for the next phase.

Developed in the US, the vaccine is the third to be added to the NHS "armoury", alongside those from Oxford-AstraZeneca PLC and Pfizer Inc.

The news comes as the government confirmed it has met its target of offering a Covid-19 vaccine to the highest priority groups by mid-April - those over the age of 50 and people who are clinically extremely vulnerable.

And the next phase of the vaccination programme - for healthy adults under the age of 50 - is expected to begin this week.

The Vaccines Taskforce has secured 17 million doses of the Moderna vaccine for the UK.

The jab has already been rolled out in Wales and Scotland, and the vaccine is expected to be delivered to people in Northern Ireland in the coming weeks.

The NHS in England confirmed that the Moderna jab will be delivered at more than 20 vaccination sites this week, including Reading's Madejski Stadium and the Sheffield Arena.

More sites will be able to deliver the jab as supply increases.

Powis said: "The Moderna rollout marks another milestone in the vaccination programme.

"We now have a third jab in our armoury and NHS staff will be using it at more than 20 sites from this week, with more coming online as supplies expand.

"England's vaccination programme is our hope at the end of a year like no other, so please do come forward and get your jab when you're invited.

"It is safe, quick and effective - it will protect you and your loved ones."

Commenting on the news, Adam Finn, a member of the JCVI, told BBC Breakfast: "This is enormously important; these are large numbers of doses, and it's another tool in the toolbox.

"We've got two excellent vaccines already that work really, really effectively but the more vaccines we've got, the more security over supply.

"I hope this is another step along the way and that we'll actually see more vaccines come through over the coming months and we'll have a really strong and secure supply.

"The programme hasn't been able to move forward quite as fast as it would have if there had been more vaccine supply this month.

"Having this additional supply of Moderna is clearly going to speed that up and enable us to get started on phase two and people in their 40s."

A 24-year-old carer from Wales became the first person in the UK to receive the jab last week.

Elle Taylor, from Ammanford, got the jab at the West Wales General Hospital in Carmarthen on April 7.

Almost 40 million vaccines have been delivered across the UK.

This includes more than 32 million first doses and 7.6 million second doses.

The number of first doses being delivered slowed throughout April due to supply constraints.

And the NHS has used the supply it has to offer those at highest risk their second jab.

In England around 94% of people aged 50 and over are likely to have had their first dose of Covid-19 vaccine.

And around 92% of those identified as clinically extremely vulnerable have had their first jab.

But officials have said the offer of a jab is "evergreen" and people who are yet to receive their first vaccine and are eligible to do so are still being encouraged to book into their local vaccination site.

Phase two of the programme will see the vaccine offered to younger healthy adults, most likely starting with those aged 40 to 49.

Regulators in the UK recommended that people aged 18 to 29 should be offered alternatives to the AstraZeneca vaccine, saying there is a possible link between the jab and "extremely rare" blood clots.

This means they could be offered the Pfizer or Moderna jab.

Public Health England released operational details about the Moderna jab on Monday, including information on the dose, the interval between first and second jab, the storage temperature and whether people who receive the jab will need to be observed afterwards.

The jab needs to be stored at minus 25C to minus 15C, and once it has been thawed it can be stored at 2C to 8C for up to 30 days.

The minimum interval between first and second dose of the Moderna vaccine is 28 days.

And patients who receive the Moderna jab will need to wait at the vaccination centre and be observed for a period of 15 minutes after they receive the vaccine.

By Ella Pickover, PA Health Correspondent

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.